• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    MyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment Drug

    12/29/23 12:45:00 PM ET
    $MYMD
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $MYMD alert in real time by email

    BALTIMORE, MD / ACCESSWIRE / December 29, 2023 / A condition that commonly affects elderly populations, sarcopenia results in the gradual loss of strength and physical function and has become an important healthcare issue worldwide in recent years. A sarcopenia diagnosis comes with a greater risk of hospitalization, disability and death. With no FDA-approved medications for sarcopenia currently on the market, there is a need for treatments that can help patients live with this disease. In Europe and the USA, the prevalence of sarcopenia with different diagnostic criteria ranges from 4.6% to 43% in communities and from 23% to 68% in clinical settings, and a high prevalence of sarcopenia can cause heavy healthcare expenditure and caregiver burden.

    But hope may be on the horizon - a pharmaceutical company's new drug could change the way this debilitating disease and others are treated.

    As a clinical-stage biopharma company, MyMD Pharmaceuticals Inc. (NASDAQ:MYMD) is committed to developing novel therapies for age-related diseases. With a focus on serious autoimmune and inflammatory diseases, the company's lead clinical candidate, MYMD-1, is a tumor necrosis factor-alpha (TNF-alpha) inhibitor with the potential to extend a healthy lifespan for sarcopenia patients.

    Positive Trial Results

    MYMD-1 studies are testing the drug's ability to slow the aging process and prevent sarcopenia. The drug's oral dosing is a significant differentiator, making it easier to use than the currently available TNF-alpha inhibitors, all of which require delivery by injection or infusion.

    MYMD-1 has shown effectiveness in pre-clinical and clinical studies in regulating the immune system through the modulation of numerous pro-inflammatory cytokines, including TNF-alpha, IL-6 and IL-17A. Unlike other therapies, MYMD-1 has shown its ability to selectively block TNF-alpha when it becomes overactivated in autoimmune diseases while allowing it to perform its normal job: being a first responder to any routine type of moderate infection. A lack of the serious side effects that are common with traditional immunosuppressive therapies that treat inflammation has also been promising during early studies of MYMD-1.

    In a recently completed phase 2 clinical trial, MYMD-1 met both of its primary endpoints, reducing the TNF-alpha, IL-6 and sTNFR1 biomarkers that are common in several chronic inflammatory diseases while meeting all secondary endpoints for safety and tolerability standards. The next-generation treatment met the secondary endpoints needed to advance the sarcopenia clinical program. The full study results will be released in 2024.

    "We are encouraged by the reduction of inflammatory markers along with the favorable safety profile demonstrated in this study of an oral TNF-alpha inhibitor," said Chris Chapman, M.D., President, Director, and Chief Medical Officer at MyMD. "Sarcopenia can significantly affect people as they age, and there are currently no approved treatments for the condition. A selective, oral treatment that reduces TNF-alpha and inflammation and does not require infusion or injection would be a welcome advance for this population."

    If approved, MYMD-1 could become the first FDA-approved drug for sarcopenia, which causes patients to have a decline in muscle mass, among other symptoms.

    MyMD Pharmaceuticals has already submitted and been approved for three Investigational New Drug Applications for MYMD-1. The company is advancing these clinical programs in chronic inflammatory conditions, including sarcopenia, rheumatoid arthritis and Hashimoto's disease, an often genetic disorder that causes inflammation of the thyroid gland.

    A small molecule that can cross the blood-brain barrier, MYMD-1 could potentially treat brain-related diseases and other autoimmune conditions such as rheumatoid arthritis. The drug's positive momentum is signaling a changing landscape for the treatment of sarcopenia and other autoimmune diseases. With a unique form of administration, MYMD-1, taken orally, could potentially completely change how autoimmune diseases are treated in the future.

    Featured photo by National Cancer Institute on Unsplash.

    Contact:

    Robert Schatz
    [email protected]

    SOURCE: MyMD Pharmaceuticals



    View the original press release on accesswire.com

    Get the next $MYMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MYMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MYMD
    SEC Filings

    See more
    • SEC Form DEF 14A filed by MyMD Pharmaceuticals Inc.

      DEF 14A - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)

      7/1/24 5:15:16 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)

      6/24/24 4:23:01 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-3 filed by MyMD Pharmaceuticals Inc.

      S-3 - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)

      6/21/24 5:14:29 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol "TNFA" Effective Before Market Open Today

      New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker symbol, "TNFA," effective before the market open today, July 24, 2024. The new trading symbol "TNFA" replaces the Company's previous trading symbol "MYMD" and coincides with the Company's previously announced corporat

      7/24/24 9:05:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.

      New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system Company plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically significant Phase 2 studies TNF Pharmaceuticals will begin trading on Nasdaq under the new trading symbol "TNFA" effective July 24, 2024 TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) (the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced a rebranding to the new name "TNF Pharmaceuticals, Inc.," effective today. The Company's com

      7/22/24 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

      Dr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® Dr. Glass brings broad expertise in regulatory strategies: 5 NDAs and MAAs, 7 pre-NDA meetings, 12 End of Phase 2 meetings, and more than 80 INDs Company announces President and CMO transition as clinical development advances through mid-stage trials Company also appoints new independent board member, Mr. Stephen Friscia, an experienced investment strategist MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflamm

      6/17/24 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Friscia Stephen

      3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

      6/28/24 4:05:18 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Pharmacyte Biotech, Inc.

      3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

      5/30/24 4:05:04 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Glass Mitchell

      3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

      5/16/24 5:30:25 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    Leadership Updates

    Live Leadership Updates

    See more
    • MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

      Dr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® Dr. Glass brings broad expertise in regulatory strategies: 5 NDAs and MAAs, 7 pre-NDA meetings, 12 End of Phase 2 meetings, and more than 80 INDs Company announces President and CMO transition as clinical development advances through mid-stage trials Company also appoints new independent board member, Mr. Stephen Friscia, an experienced investment strategist MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflamm

      6/17/24 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board

      MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that it has appointed David Rini to the Company's Scientific Advisory Board. "I am delighted to join the MyMD Scientific Advisory Board and look forward to working on the development and communication about our two platforms," stated David Rini. David Rini is a Professor at the Johns Hopkins University School of Medicine in the Department of Art of Applied to Medicine, Cellular and Molecular Medicine, and Director of the Medical and Biological Illustration Graduate Program. Professor Rini earned his M

      5/17/21 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    Financials

    Live finance-specific insights

    See more
    • MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results

      MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced statistically significant positive topline Phase 2 results for its next generation Oral TNF-α inhibitor MYMD-1 in Sarcopenia/Age-Related Frailty earlier this week. In conjunction with its release, the company also announced it will hold a conference call today, August 2nd, at 4:30pm ET to discuss the results. To participate in the conference call, please register here. A webcast can also be accessed under the ‘Events & Presentations' section on the Investors page at w

      8/2/23 8:30:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty

      - MYMD-1 significantly reduced serum levels of chronic inflammatory markers and met all primary pharmacokinetic and secondary safety and tolerability endpoints across multiple doses over 28 days of treatment - MYMD-1 demonstrated statistical significance across three biomarkers: TNF-α (P=0.008), sTNFR1 (P=0.02), and IL-6 (P=0.03) - First Oral TNF-α inhibitor, if approved, would offer potential patient benefit in large markets - Company to present the data to FDA and intends to advance the clinical program for MYMD-1; will hold conference call on August 2, 2023, at 4:30 PM Eastern Time MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage pharmaceutica

      7/31/23 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by MyMD Pharmaceuticals Inc.

      SC 13D - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

      5/30/24 4:05:03 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by MyMD Pharmaceuticals Inc.

      SC 13G - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

      2/14/24 3:13:35 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by MyMD Pharmaceuticals Inc. (Amendment)

      SC 13G/A - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

      2/14/24 11:27:33 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care